Using gel filtration chromatography, we evaluated aluminum bound to albumin, transferrin, and other plasma proteins in the serum of patients on maintenance hemodialysis. The proportion of dialyzable aluminum, as determined by selective membrane ultrafiltration and flameless atomic absorption spectrometry, increased by more than fourfold on treatment with the metal chelator, deferoxamine. This ultrafiltration technique may prove useful for monitoring the proportion of aluminum mobilized during such therapy.
Samples
Blood was sampled into 10-mL red-top Vacutainer Tubes (Becton Dickinson Co., Rutherford, NJ 07070). Individuals who had not received aluminum-containing antacids served as control subjects; they included 10 healthy laboratory staff and 24 hospitalized patients with normal renal function. Serum aluminum concentrations were monitored in uremic patients who were undergoing hemodialysis therapy at this hospital. From this group, 20 with Al concentrations >75 ,ugfL were given DFO, administered intravenously over 2 h in 500 mL of 50 g/L dextrose solution at a dose of 100 mg/kg body weight (to a maximum of 6.0 g). Blood was sampled for Al determination before the DFOinfusion (before the initial hemodialysis), after DFO infusion (following the second hemodialysis), and then 48 h after the DFO infusion. This cycle was repeated after approximately one week, according to the patient's regular dialysis schedule.
Procedures
Total serum Al was determined by flameless atomic absorption spectrometry (AAS) as previously described (10). Assay precision was monitored with "in-house" qualitycontrol sera (11), for which the within-run and between-run CVs were 5% and 8%, respectively. Analytical recovery of Al added to serum (to 200 ,ug/L) ranged between 95 and 103% by the method of standard additions.
The Al content of serum ultrafiltrates (A1UF) was determined by a method similar to that described above for total serum Al. Approximately 1 mL of whole serum was centrifuged (1500 x g, 15 mm, 4#{176}C) in a Centrifree Micropartition Unit. The clear, colorless fluid that passed through the membrane filter was collected in the lower chamber of the unit and used for analysis.
Serum Al samples were fractionated by gel-ifitration chromatography on 2 x 65 cm columns of Bio-Gel P-2. The columns were equilibrated and samples eluted, 1-mL fractions being collected, at a rate of 36 mLfh. The eluent was a solution containing 120 mmol of NaC1, 6 mmol of NaOH, 3 mmol of NaN3, 1 mmol of CaCl2, 0.5 mmol of MgCl2, 4 mmol of KC1, 40 mmol of Na.HCO3, and 10 mmol of Tris (pH 7.4 at 18 #{176}C) per litre.
The fractions were monitored at 280 nm and then total protein was determined by the Coomassie Brilliant Blue binding method of Bradford (12), with a protein assay kit (Bio-Rad Laboratories (Canada) Ltd., Mississauga, Ont. L4X 2A9), and albumin by the bromcresol green dyebinding method (13). Transferrin was detected immunochemically in the column fraction by use of the Ouchterlony diffusion technique. Al was determined in these fractions by AAS as described above.
Deferoxamine (in de-ioni.zed water) was measured at 212 nm in a Model DU-8 spectrophotometer (Beckman Instruments Inc., Fullerton, CA 92634). The maximum absorbance wavelength shifted to 204 rim when a complex between DFO and Al was formed (Figure 1 ). This wavelength was used to detect the complex in aqueous solutions 203.92 nm DFO to these patients, the total Al in the serum increased I -21I.97nm by more than twofold (p <0.001) while the proportion of Alur increased by more than fourfold (p <0.001). Figure 2 shows histograms illustrating the proportion of Alur and bound Al for two patients on a regimen of twice weekly hemodialysis and approximately weekly infusions of DFO. These two patients illustrate that, before DFO infusion, the proportion of A1UF is about the same (50%) in both patients. Immediately after the first DFO infusion, the proportion of AlUF increased to 87% and 76% for patients A and B, respectively. The absolute magnitude of Al is quite different in these two patients, probably reflecting differences in initial Al burden. Patient A showed less overall fluctuation in total serum Al concentration over three cycles, while patient B's response was more typical of that after DFO infusions. In both, the proportion of AljJj? remained relatively high (>75%) 48 h after DFO infusion. We used Student's t-test with log transformation of data to determine the distribution parameters and the confidence limits of concentrations of Al among the control subjects. We used the paired t-test to determine these values for data obtained before and after DFO treatment. Figure 4 (left) shows a typical elution profile of a serum sample containing 95 ,ug of Al per litre, from a patient on maintenance hemodialysis before DFO treatment. In this profile, the first peak contained most of the high-Mr proteins (including albumin and transferrin), which overlapped a major Al peak.
Results
At least three further peaks of Al appeared when the gel was eluted, and they appear to represent Al bound to other, as-yet-unidentified, serum constituents with molecular masses <1800 Da. These fractions do not represent "free" Al, because ionized Al is bound by the polyacrylamide gel and can only be removed by passing DFO through the column. In this patient, after treatment with DFO, total serum Al increased by about threefold (to 275 g/L). The elution proffle from gel chromatography of this sample is shown in Figure 4 (right) . There is a noticeable shift in the positions of the Al fractions as compared with the first elution pattern (Figure 4 (left) ). In the second pattern, the initial Al peak did not co-elute with the proteins (transferrin and albumin), but was eluted later, as indicated by the arrow (Figure 4 (right) ). This corresponded to the position of the DFO:Al complex as determined earlier with use of standard aqueous reagents (Figure 3) . Evidently, after DFO therapy, bound Al is displaced from its binding sites on high-Mr proteins, becoming attached to DFO, and this 0.I DFO:Al complex probably contributes to the increased ATJF detected in patients after chelation therapy. A shift in the third peak (fractions 52-62) of Al is also observed. The elution profile of the Al fractions in this major peak suggests a molecular mass of less than 500 Da, allowing dialysis through membranes that retain molecules of mass greater than 1000 Da.
Discussion
This study shows, by ultrafiltration in vitro, that a relatively large proportion of Al in serum is bound to plasma constituents, both in subjects with normal renal function and in uremic patients. This agrees with current reports that approximately 80% of the Al in serum is protein bound (14, 15) and is not diffusible through dialysis membranes. By the use of gel filtration chromatography we found that Al co-elutes with albumin and transferrin (as well as other unidentified constituents)
as reported by King et al. (16) and Trapp (4) . Trapp demonstrated by in vivo studies with 67Ga that Al ion is bound to one of two specific sites on serum transferrin. The binding of Al to transferrin is in direct competition with that of iron, which suggests a causative role for Al in the development of microcytic anemia that is not ascribable to iron deficiency (17) , but further studies are required to see if this is so.
Since the introduction, in 1979, of DFO to remove Al from a patient with severe dialysis encephalopathy (6), this ironchelating agent has been successfully used to treat cases of Al intoxication (7) (8) (9) . Recent studies by Day et al. (18) suggest that DFO forms a six-coordinate 1:1 complex with the three available electrons of Al. In aqueous solution, this DFO:Al complex shows a characteristic maximum at 204 nm, as compared with 212 nm for DFO alone (Figure 1) . In serum samples or ultra.ffltrates of serum, it was not possible to measure DFO or its complex by spectrophotometry because of the high ultraviolet absorbance of the matrix at these wavelengths (Figure 1) .
The ability of DFO to chelate Al and displace it from protein binding sites is clearly demonstrated by the shift in the gel filtration pattern of uremic patient sera before and after chelation therapy with DFO (Figure 4) . The increase in total serum Al concentration after DFO infusion in several of the patients in this study, as illustrated in Figure  2B , is consistent with reports that DFO mobilizes Al in vivo from tissue and bone deposits (6, 8, 9, 19) .
During hemodialysis, the DFO:Al complex, which has an Mr of about 587, is able to pass through the dialysis membrane into the dialysis fluid under a suitable diffusion gradient. By the use of selective membrane ifiters (molecular mass cutoff about 1000 Da) in the Amicon ultrafiltration apparatus, under centrifugal pressure, we were able to assess the proportion of Al available for removal by hemodialysis. For example, a patient's AlUF before DFO treatment was 13.2%, which increased to 92.8% after DFO infusion and 48 h later was 84.9%. Another area in which the monitoring of the total Al and the AlUF was useful is in the magnitude of the response to DFO therapy. As illustrated in Figure 2B , a marked increase in Al was obtained in the initial infusion, which was reduced by about half in a subsequent DFO treatment. Because the Al burden differs in different patients, as also does the degree of Al mobilization with the chelator, the ultrafiltration technique can provide useful information on the status of A1UFfor removal by bemodialysis.
